Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Fig. 1

Study flow chart. A series of interconnected analyses is reported, with progressive exclusions. FAERS, FDA adverse event reporting system. SGLT2i, sodium glucose cotransporter-2 inhibitors. ATC anatomical therapeutic classification, AE adverse event, CVD cardiovascular disease, RD renal disease, GUTI genito-urinary tract infections, DKA diabetic ketoacidosis, FG Fournier’s gangrene. Numbers are referred to the total number or reports in each analysis (*with the diabetes indication)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840